Ignite Creation Date:
2024-05-06 @ 3:24 PM
Last Modification Date:
2024-10-26 @ 1:49 PM
Study NCT ID:
NCT04629703
Status:
COMPLETED
Last Update Posted:
2023-08-18
First Post:
2020-11-13
Brief Title:
Double-Blind Randomized Placebo-Controlled Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
Sponsor:
Rigel Pharmaceuticals
Organization:
Rigel Pharmaceuticals
Study Overview
Official Title:
Double-Blind Randomized Placebo-Controlled Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
Status:
COMPLETED
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is a double-blind randomized placebo-controlled multi-center Phase 3 study to evaluate the efficacy and safety of fostamatinib in COVID-19 subjects
Detailed Description:
The primary objective of this study is
To evaluate the efficacy of fostamatinib when used in combination with standard of care SOC in subjects hospitalized with COVID- 19 and requiring oxygen supplementation as measured by days on oxygen
To evaluate the efficacy of fostamatinib when used in combination with standard of care SOC in subjects hospitalized with COVID- 19 and requiring oxygen supplementation as measured by days on oxygen
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None